The Battle is going on for Biological and their biosimilars, according to the manufacturers of Biological the bill passed by US congress allows them 12 years of data exclusivity and according to payers it 12 years of market exclusivity and if we favor the manufacturers point of view then we will be denying the patients their right of cheap medication in the form of Biosimilars .......so in US till now innovator mono poly exists .......It’s good that we don't have price monopoly here in India. I have been observing for long over the last two years Top 5 big pharma's are going for Biosimilar pathway .......I hope we might see some alteration in the rules for biosimilars in United States within 1-2 years.....
No comments:
Post a Comment